Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy
E Martin, AV Thougaard, M Grauslund, PB Jensen… - Toxicology, 2009 - Elsevier
Anthracycline-induced cardiomyopathy is a major problem in anti-cancer therapy. The only
approved agent for alleviating this serious dose limiting side effect is ICRF-187
(dexrazoxane). The current thinking is that the ring-opened hydrolysis product of this agent,
ADR-925, which is formed inside cardiomyocytes, removes iron from its complexes with
anthracyclines, hereby reducing the concentration of highly toxic iron–anthracycline
complexes that damage cardiomyocytes by semiquinone redox recycling and the production …
approved agent for alleviating this serious dose limiting side effect is ICRF-187
(dexrazoxane). The current thinking is that the ring-opened hydrolysis product of this agent,
ADR-925, which is formed inside cardiomyocytes, removes iron from its complexes with
anthracyclines, hereby reducing the concentration of highly toxic iron–anthracycline
complexes that damage cardiomyocytes by semiquinone redox recycling and the production …